Business
Cipher Pharmaceuticals announces Canadian launch of Beteflam(TM)
Cipher Pharmaceuticals announces Canadian launch of Beteflam™ Cipher Pharma...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCipher Pharmaceuticals announces Canadian launch of Beteflam™\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nCipher Pharmaceuticals announces Canadian launch of Beteflam™\nCanada NewsWire\nMISSISSAUGA, ON, April 5, 2016\n\n\n\nRepresents Fourth Product in Cipher's Growing Canadian Portfolio\n\n\n\nMISSISSAUGA, ON, April 5, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (\"Cipher\" or \"the Company\") today announced the Canadian launch of Beteflam™ (betamethasone valerate), a novel, patent-protected patch, indicated for the treatment of mild to moderate plaque psoriasis of the elbows and knees for a maximum duration of 30 days in adult patients1.\n\n\"We're pleased to introduce Beteflam, a unique treatment option for Canadians suffering from plaque psoriasis, a very common and persistent skin disorder, affecting as many as a million Canadians2,\" said Joan Chypyha, GM of Cipher Canada. \"We continue to deliver on our portfolio expansion plans and our commitment to delivering unique Dermatology products. Beteflam represents our fourth marketed product, and we expect to continue our growth with six products targeted for the Canadian market in 2016 and eight in 2017.\"\n\nTopical corticosteroids remain the primary treatment for steroid-responsive inflammatory skin diseases, including mild to moderate chronic plaque psoriasis. Occlusion with plastic film dressings is a widely accepted procedure to enhance their efficacy, especially in the treatment of psoriasis. Beteflam is a topical patch that is applied once daily to the affected region and may be cut to fit the particular size and shape of the psoriatic lesion thereby reducing potential contact of the steroid with healthy areas of skin.\n\nCipher licensed the Canadian rights to Beteflam from Institut Biochimique SA (\"IBSA\"). The efficacy and safety of Beteflam was demonstrated by two randomized, active-controlled studies involving 555 patients with mild-to-moderate chronic plaque psoriasis, of which 281 patients received Beteflam. ...